- Company
- Tevimbra may be prescribed in general hospitals in KOR
- by Eo, Yun-Ho Sep 2, 2024 05:48am
- The immuno-oncology drug 'Tevimbra' may now be prescribed in general hospitals in Korea. According to industry sources, BeiGene Korea's PD-1 inhibitor Tevimbra (tiselizumab) has passed the drug committees (DCs) of tertiary hospitals, including Samsung Medical Center and Seoul National University Hospital. In addition, the company succe
- Policy
- Nicergoline for dementia listed at 50% of the highest-priced
- by Lee, Tak-Sun Sep 2, 2024 05:48am
- Before March this year, there were only two products containing the active ingredient nicergoline available. However, the number quickly increased, resulting in nearly a 50% difference between the highest and lowest prices. The prices of the listed products are getting cheaper with a stepwise pricing system applied. This reflects that more
- Policy
- Lily's orphan drug 'Jaypirca' receives conditional approval
- by Lee, Hye-Kyung Aug 30, 2024 05:50am
- 'Jaypirca,' a designated orphan drug for the treatment of Mantle Cell Lymphoma that recently received marketing authorization in South Korea, is expected to submit the Phase 3 trial results showing therapeutic confirmation by March 2027. As it received conditional approval based on Phase ½ clinical trial results, the company must compare
- Policy
- Reimb standards set for biliary tract cancer drug Pemazyre
- by Lee, Tak-Sun Aug 30, 2024 05:50am
- Pemazyre (pemigatinib), a targeted therapy for biliary tract cancer supplied to Korea by Handok, has successfully received reimbursement standards from the Health Insurance Review and Assessment Service's Cancer Disease Review Committee (CDDC). The reimbursement standards for the immuno-oncology drug Tevimbra were also set at the meeting. Mer
- Company
- API competition↑ with entry of Chinese and Indian pharmas
- by Son, Hyung-Min Aug 30, 2024 05:50am
- Chinese and Indian companies developing active pharmaceutical ingredients (APIs) are accelerating their entry into Korea. Numerous Chinese and Indian companies as well as domestic companies participated in 'CPHI Korea 2024,' an exhibition for the global pharmaceutical, bio, and health functional food industry that was held at COEX in Samseong-do
- Company
- Anti-cancer drug trends changes from IV→SC
- by Moon, sung-ho Aug 30, 2024 05:50am
- Global pharmaceutical companies speed up the development of subcutaneous (SC) formulations of their proprietary intravenous (IV) medications. To overcome the disadvantage of IV formulation medications that have long administration duration, more anti-cancer drugs are shifting to SC formulations. Following the trend, Korean companies with SC
- Company
- K-bio jumps into developing new drugs for pancreatic cancer
- by Son, Hyung-Min Aug 30, 2024 05:50am
- Korean pharmaceutical and biotech companies have jumped into the development of new drugs for pancreatic cancer, which is categorized as refractory cancer. Prestige Biopharma, New Cancer Cure Bio (NCC-Bio), LigaChem Biosciences, and Aptamer Sciences are conducting clinical trials to challenge the field. These companies plan to investigate the co
- Policy
- Prices of Dukarb, Rosuzet cut 3 yrs through PVA
- by Lee, Tak-Sun Aug 30, 2024 05:49am
- The insurance ceiling price of 6 drugs has been cut for 3 consecutive years through the price-volume agreement ‘Type C’ negotiations. According to the industry on the 28th, 6 drugs, including Boryung Pharmaceutical’s 'Dukarb', Dong-A ST 'Growtropin II Inj’, Hanmi Pharmaceutical’s 'Rosuzet Tab', Janssen Korea’s 'Concerta Oros ER Tab’
- Opinion
- [Reporter's View] pros and cons of concurrent reimb listing
- by Eo, Yun-Ho Aug 30, 2024 05:49am
- When there are no changes to demand, increased supply reduces prices. This model of price determination can be applied to the pharmaceutical market. For pharmaceuticals, inducing competition between pharmaceutical companies can decrease financial expenses. However, it often results in increased time for reimbursement listing. Drug price
- Company
- Korean pharma and biotechs expand R&D investments
- by Chon, Seung-Hyun Aug 29, 2024 04:32am
- Listed pharma and biotech companies have expanded their research and development (R&D) investments in Korea this year. 3 out of 5 major pharmaceutical companies increased their R&D investments from last year to discover new candidates. Pharmaceutical companies with larger sales have been more active in reinvesting in R&D. According to the Fin
